Skip to content

CLBR Per Initial Cycle With Different Starting Dose in Aged Patients With Poor Ovarian Reservation: 300IU Versus 150IU

Comparison of Cumulative Live Birth Rate Per Initial Cycle Between 300 IU and 150IU Starting Dose of rFSH Among Aged Patients With Poor Ovarian Reservation: a Randomized Controlled Trail

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03914651
Enrollment
260
Registered
2019-04-16
Start date
2019-04-23
Completion date
2022-12-30
Last updated
2022-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Brief summary

Among aged patients with poor ovarian reservation(defined as age 35 to 42 years; antral follicle count(AFC)≤ 5 or anti-mullerian hormone(AMH)≤ 1.2 ng/ml), cumulative live birth rate(CLBR) and time to live birth(TTLB) of the first stimulation cycle were compared between a starting dose of 300IU or 150IU rFSH in controlled ovarian stimulation with gonadotropin-releasing hormone(GnRH)antagonist protocol. This study is a prospective randomized controlled trial.

Interventions

DRUG300IU rFSH Gonal-F® starting dose during controlled ovarian stimulation

On menstrual cycle day 2 or day 3, 300IU rFSH Gonal-F® will be administrated daily till the day of trigger. The dosage of rFSH can be adjusted only if there is a risk of ovarian hyperstimulation syndrome(OHSS).

DRUG150IU rFSH Gonal-F® starting dose during controlled ovarian stimulation

On menstrual cycle day 2 or day 3, 150IU rFSH Gonal-F® will be administrated daily till the day of trigger. The dosage of rFSH can be adjusted only if there is a risk of OHSS or insufficient follicular growth.

Sponsors

Reproductive & Genetic Hospital of CITIC-Xiangya
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
35 Years to 42 Years
Healthy volunteers
No

Inclusion criteria

1. Age Limits≥35 and≤42; 2. AFC≤5 or AMH≤1.2ng/ml; 3. BMI≤30kg/m2; 4. The first IVF/intracytoplasmic sperm injection (ICSI) cycle;

Exclusion criteria

1. Any other underlying disease or condition considered IVF is contraindicated. 2. Ovarian hyperstimulation syndrome(PCOS), moderate or severe intrauterine adhesion,untreated hydrosalpinx, adenomyosis, any myoma in cases that endometrium was affected, intramural larger than 4cm. 3. Autoimmune antibody positive, untreated. 4. History of recurrent miscarriages. 5. Patients seeking for Preimplantation Genetic Testing(PGT) treatment. 6. Simultaneous participation in another clinical study. 7. According to the judgment of the investigator, any reason or condition that precludes subject for participating in the study.

Design outcomes

Primary

MeasureTime frameDescription
Cumulative live birth rate22 monthsLive birth is defined as the delivery of any viable infant at 28 weeks or more of gestation after our interventions。And cumulative live birth rate is calculated by dividing the number of women achieving live birth after transfers of all study-specific embryos (within 1 year after randomization) by the total number of women randomized to the specific group.

Secondary

MeasureTime frameDescription
Multiple pregnancy rate22 monthsNumber of multiple pregnancies / number of clinical pregnancies over (up to) 3 transfers within 1 year.
Neonatal malformation rate22 monthsNumber of infant diagnosed as neonatal malformation / the total number of infant delivered after 28 weeks of gestation.
Good quality embryo rate1 monthGood quality embryo is defined as embryo that is graded as 6CII or better or blastocyst. And good quality embryo rate is calculated by dividing the number of good quality embryo by the total number of embryo obtained after fertilization in the specific group.
Time to live birth22 monthsTime to live birth is defined as the interval between the date of randomization and achieving live birth.
Birth weight22 monthsWeight of newborns at delivery
Number of MII eggs1 monthMII eggs is defined as eggs retrieved that reach the MII phase.
Cumulative Clinic pregnancy rate14 monthsClinic pregnancy will be diagnosed with the detection of an intrauterine gestation sac. And cumulative clinic pregnancy rate is calculated by the number of women who achieves clinical pregnancy after transfers of all study-specific embryos (within 1 year after randomization) by the total number of women randomized to the specific group.
cumulative pregnancy loss rate19 monthsPregnancy loss is defined as a complete spontaneous abortion or a nonviable pregnancy before 28 weeks of gestation. And cumulative pregnancy loss rate is calculated as the number of pregnancy losses / number of clinical pregnancy after transfers of all study-specific embryos (within 1 year after randomization).
Implantation rate14 monthsNumber of gestation sac detected / number of embryo transferred.
Cycle cancellation rate1 monthCycle cancellation is defined as cycle cancelled before obtaining at least one viable embryo for any reason. And cycle cancellation rate is calculated by dividing the number of women cancelled their cycle before obtaining at least one viable embryo for any reason by the total number of women randomized to the specific group.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026